Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
Italy Investigates Microsoft Over Microsoft 365 AI Subscription Price Hike 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Nomura Stock Upgraded to Buy by BofA as Stronger ROE and Earnings Growth Boost Outlook 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
China Eastern Orders 25 Airbus A330neo Jets in $9.35 Billion Deal to Boost International Expansion 
Heidelberg, Germany, February 28, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Florian Fischer, CFO, will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 10:40 a.m. (ET) in Boston.
A live webcast of the conference presentation can be accessed through the "Events" section on the "Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the presentation will be available from Affimed's website for 30 days following the respective conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected]
